Your browser doesn't support javascript.
loading
Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors.
Dageforde, Leigh Anne; Vachharajani, Neeta; Tabrizian, Parissa; Agopian, Vatche; Halazun, Karim; Maynard, Erin; Croome, Kristopher; Nagorney, David; Hong, Johnny C; Lee, David; Ferrone, Cristina; Baker, Erin; Jarnagin, William; Hemming, Alan; Schnickel, Gabriel; Kimura, Shoko; Busuttil, Ronald; Lindemann, Jessica; Florman, Sander; Holzner, Matthew L; Srouji, Rami; Najjar, Marc; Yohanathan, Lavanya; Cheng, Jane; Amin, Hiral; Rickert, Charles A; Yang, Ju Dong; Kim, Joohyun; Pasko, Jennifer; Chapman, William C; Majella Doyle, Maria B.
Afiliação
  • Dageforde LA; Massachusetts General Hospital, Boston, MA. Electronic address: ldageforde@mgh.harvard.edu.
  • Vachharajani N; Washington University in St Louis, Saint Louis, MO.
  • Tabrizian P; Icahn School of Medicine at Mount Sinai, New York, NY.
  • Agopian V; UCLA School of Medicine, Los Angeles, CA.
  • Halazun K; Weill Cornell Medicine, New York, NY.
  • Maynard E; Oregon Health and Science University, Portland, OR.
  • Croome K; Mayo Clinic, Jacksonville, FL.
  • Nagorney D; Mayo Clinic, Rochester, MN.
  • Hong JC; Medical College of Wisconsin, Milwaukee, WI.
  • Lee D; Medical College of Wisconsin, Milwaukee, WI.
  • Ferrone C; Massachusetts General Hospital, Boston, MA.
  • Baker E; Atrium Health, Charlotte, NC.
  • Jarnagin W; Memorial Sloan Kettering Cancer Center, New York, NY.
  • Hemming A; University of Iowa, Iowa City, IA.
  • Schnickel G; University of California San Diego, San Diego, CA.
  • Kimura S; University of Iowa, Iowa City, IA.
  • Busuttil R; UCLA School of Medicine, Los Angeles, CA.
  • Lindemann J; Washington University in St Louis, Saint Louis, MO.
  • Florman S; Icahn School of Medicine at Mount Sinai, New York, NY.
  • Holzner ML; Icahn School of Medicine at Mount Sinai, New York, NY.
  • Srouji R; Washington University in St Louis, Saint Louis, MO.
  • Najjar M; Columbia University Irving Medical Center, New York, NY.
  • Yohanathan L; Mayo Clinic, Rochester, MN.
  • Cheng J; Beth Israel Deaconess Medical Center, Boston, MA.
  • Amin H; Atrium Health, Charlotte, NC.
  • Rickert CA; Massachusetts General Hospital, Boston, MA.
  • Yang JD; Cedars-Sinai Medical Center, Los Angeles, CA.
  • Kim J; Atrium Health, Milwaukee, WI.
  • Pasko J; Providence Health Care, Spokane, WA.
  • Chapman WC; Washington University in St Louis, Saint Louis, MO.
  • Majella Doyle MB; Washington University in St Louis, Saint Louis, MO.
J Am Coll Surg ; 232(4): 361-371, 2021 04.
Article em En | MEDLINE | ID: mdl-33316425
BACKGROUND: Combined hepatocellular-cholangiocarcinoma liver tumors (cHCC-CCA) with pathologic differentiation of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma within the same tumor are not traditionally considered for liver transplantation due to perceived poor outcomes. Published results are from small cohorts and single centers. Through a multicenter collaboration, we performed the largest analysis to date of the utility of liver transplantation for cHCC-CCA. STUDY DESIGN: Liver transplant and resection outcomes for HCC (n = 2,998) and cHCC-CCA (n = 208) were compared in a 12-center retrospective review (2009 to 2017). Pathology defined tumor type. Tumor burden was based on radiologic Milan criteria at time of diagnosis and applied to cHCC-CCA for uniform analysis. Kaplan-Meier survival curves and log-rank test were used to determine overall survival and disease-free survival. Cox regression was used for multivariate survival analysis. RESULTS: Liver transplantation for cHCC-CCA (n = 67) and HCC (n = 1,814) within Milan had no significant difference in overall survival (5-year cHCC-CCA 70.1%, HCC 73.4%, p = 0.806), despite higher cHCC-CCA recurrence rates (23.1% vs 11.5% 5 years, p < 0.001). Irrespective of tumor burden, cHCC-CCA tumor patient undergoing liver transplant had significantly superior overall survival (p = 0.047) and disease-free survival (p < 0.001) than those having resection. For cHCC-CCA within Milan, liver transplant was associated with improved disease-free survival over resection (70.3% vs 33.6% 5 years, p < 0.001). CONCLUSIONS: Regardless of tumor burden, outcomes after liver transplantation are superior to resection for patients with cHCC-CCA. Within Milan criteria, liver transplant for cHCC-CCA and HCC result in similar overall survival, justifying consideration of transplantation due to the higher chance of cure with liver transplantation in this traditionally excluded population.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Fígado / Neoplasias Complexas Mistas / Colangiocarcinoma / Carcinoma Hepatocelular / Hepatectomia / Neoplasias Hepáticas / Recidiva Local de Neoplasia Tipo de estudo: Evaluation_studies / Observational_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Revista: J Am Coll Surg Assunto da revista: GINECOLOGIA / OBSTETRICIA Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Fígado / Neoplasias Complexas Mistas / Colangiocarcinoma / Carcinoma Hepatocelular / Hepatectomia / Neoplasias Hepáticas / Recidiva Local de Neoplasia Tipo de estudo: Evaluation_studies / Observational_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Revista: J Am Coll Surg Assunto da revista: GINECOLOGIA / OBSTETRICIA Ano de publicação: 2021 Tipo de documento: Article